Successful NIHR grant Philip Fowler, 29th June 20185th August 2018 Last year I coordinated a bid to the NIHR for capital to improve our research capacity to study antimicrobial resistance (AMR) at the Oxford Biomedical Research Centre. We were successful and were awarded £1.8 million to fund several different activities, including developing vaccines to prevent the spread of AMR. Previously in the John Radcliffe hospital Clinical Microbiology had one small second-generation genetic sequencer; now as a result of the grant we have a second, but more crucially, two very high-throughput third-generation genetic sequencers. These are GridIONs from Oxford Nanopore and sequence DNA in a completely different way that could revolutionise the use of genetics in Clinical Microbiology. Grants like this all too-often often focus on the experimental equipment at the expense of the compute and storage you need to analyse and store the data. We were fortunate to secure funds to provide a small processing cluster in the room next to the sequencing facility in addition to much larger storage and compute at the Big Data Institute, part of which my group will be able to use to continue to develop methods for de novo prediction of the effect of individual protein mutations on the actions of antibiotics. Share this: Click to share on X (Opens in new window) X Click to share on Bluesky (Opens in new window) Bluesky Click to email a link to a friend (Opens in new window) Email Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Mastodon (Opens in new window) Mastodon Related antimicrobial resistance clinical microbiology grants research
antimicrobial resistance Twitter at #ECCMID 27th April 20175th August 2018 A bit over two years ago I was a guest blogger at the US Biophysical… Share this: Click to share on X (Opens in new window) X Click to share on Bluesky (Opens in new window) Bluesky Click to email a link to a friend (Opens in new window) Email Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Mastodon (Opens in new window) Mastodon Read More
SARS-CoV-2 pipeline live on EIT Pathogena 28th January 202528th January 2025 Back in the SARS-CoV-2 pandemic we worked closely with ORACLE Corp to build and deploy… Share this: Click to share on X (Opens in new window) X Click to share on Bluesky (Opens in new window) Bluesky Click to email a link to a friend (Opens in new window) Email Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Mastodon (Opens in new window) Mastodon Read More
antimicrobial resistance I’ve moved… 14th March 20165th August 2018 Today is my first day as a Senior Researcher in Modernising Medical Microbiology in the… Share this: Click to share on X (Opens in new window) X Click to share on Bluesky (Opens in new window) Bluesky Click to email a link to a friend (Opens in new window) Email Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Mastodon (Opens in new window) Mastodon Read More